Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBES1TY: Semaglutide for Obesity in Adults with Type 1 Diabetes
2025-522326-13-00Phase 3Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and diabetes mellitus type 1 (T1D) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Body weight and BMI. Planned start Sep 2025; status: authorised.
02
Drugs
03
Conditions
obesitydiabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2025-522326-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522326-13-00.